Get the Stockscreener App
3.78
5.59%
0.20
Pre-market:
3.82
0.04
+1.06%
Larimar Therapeutics Inc stock is traded at $3.78, with a volume of 1.34M.
It is up +5.59% in the last 24 hours and up +11.83% over the past month.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
See More
Previous Close:
$3.58
Open:
$3.64
24h Volume:
1.34M
Relative Volume:
1.03
Market Cap:
$323.53M
Revenue:
-
Net Income/Loss:
$-36.95M
P/E Ratio:
-4.50
EPS:
-0.84
Net Cash Flow:
$-33.46M
1W Performance:
+14.20%
1M Performance:
+11.83%
6M Performance:
+20.00%
1Y Performance:
-50.78%
1-Day Range:
$3.5113
$3.79
1-Week Range:
$3.415
$4.2252
52-Week Range:
$1.61
$9.50
Larimar Therapeutics Inc Stock (LRMR) Company Profile
Name
Larimar Therapeutics Inc
Sector
Industry
Phone
844-511-9056
Address
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Compare LRMR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
3.78 | 306.41M | 0 | -36.95M | -33.46M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
374.46 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
435.00 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.94 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
638.90 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
289.75 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-25 | Initiated | Truist | Buy |
| Oct-16-24 | Initiated | Oppenheimer | Outperform |
| Oct-03-24 | Initiated | Wedbush | Outperform |
| Oct-02-24 | Initiated | H.C. Wainwright | Buy |
| Sep-04-24 | Initiated | Robert W. Baird | Outperform |
| Apr-03-24 | Initiated | Leerink Partners | Outperform |
| Nov-17-23 | Upgrade | Citigroup | Neutral → Buy |
| Oct-19-22 | Initiated | Guggenheim | Buy |
| Feb-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Feb-10-21 | Initiated | JMP Securities | Mkt Outperform |
| Feb-01-21 | Initiated | William Blair | Outperform |
View All
Larimar Therapeutics Inc Stock (LRMR) Latest News
What are Larimar Therapeutics Inc.’s recent SEC filings showingBest Small Caps with Big Returns - classian.co.kr
Will Larimar Therapeutics Inc. stock recover after earningsDouble Return Opportunity Watch - thegnnews.com
Will Larimar Therapeutics Inc. benefit from rising consumer demandTop Earnings Growth Momentum Picks - newsyoung.net
Larimar Therapeutics: Institutional Confidence and Capital-Raising Strategy Signal Conviction in Long-Term Pipeline - AInvest
Institutional Investors Hold 40% Stake in Larimar Therapeutics - AInvest
With 40% stake, Larimar Therapeutics, Inc. (NASDAQ:LRMR) seems to have captured institutional investors' interest - Yahoo Finance
Larimar Therapeutics Aligns with FDA Guidance, Revises Nomlabofusp Submission Timeline - MSN
Larimar Therapeutics Sees Significant Stock Purchase by Director - AInvest
Larimar Therapeutics Stock (LRMR) Opinions on Public Offering Announcement - Quiver Quantitative
Mintz Advises on Larimar Therapeutics’ $69 Million Public Offering - Mintz
Larimar Therapeutics Insider Bought Shares Worth $30,000,000, According to a Recent SEC Filing - MarketScreener
Massive Stock Purchase by Larimar Therapeutics Director! - TipRanks
Larimar therapeutics: Deerfield funds buy $10.8m in shares By Investing.com - Investing.com Canada
Larimar therapeutics: Deerfield funds buy $10.8m in shares - Investing.com India
Larimar Therapeutics stock price target lowered to $10 at Jones Trading - Investing.com Canada
Why is Larimar Therapeutics Inc. stock attracting strong analyst attentionCapitalize on high-growth stocks early - Jammu Links News
What analysts say about Larimar Therapeutics Inc. stockCapitalize on high-yield stocks early - Jammu Links News
What institutional investors are buying Larimar Therapeutics Inc. stockAchieve exceptional returns with expert guidance - Jammu Links News
What catalysts could drive Larimar Therapeutics Inc. stock higher in 2025Build wealth steadily with expert advice - Jammu Links News
How does Larimar Therapeutics Inc. compare to its industry peersBuild a portfolio that withstands market volatility - Jammu Links News
What are analysts’ price targets for Larimar Therapeutics Inc. in the next 12 monthsUnmatched profit potential - Jammu Links News
Should I hold or sell Larimar Therapeutics Inc. stock in 2025Discover stocks with strong growth potential - Jammu Links News
Is Larimar Therapeutics Inc. a good long term investmentCapitalize on market shifts before others do - Jammu Links News
What are the technical indicators suggesting about Larimar Therapeutics Inc.Unlock powerful market insights for success - Jammu Links News
What are Larimar Therapeutics Inc. company’s key revenue driversDiscover breakthrough stocks before the crowd - Jammu Links News
Larimar Therapeutics Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Larimar Therapeutics raises $69 million in public offering - Investing.com
Larimar Therapeutics raises $69 million in public offering By Investing.com - Investing.com Nigeria
Larimar Therapeutics Announces $64.4 Million Stock Offering - The Globe and Mail
Why Larimar Therapeutics Inc. is moving todayAutomated AI Forecast with Trading Alerts - Newser
Relative strength of Larimar Therapeutics Inc. in sector analysisSmart Trade Mapping with Entry Details - Newser
Analyzing recovery setups for Larimar Therapeutics Inc. investorsOversold Reversal Picks with Buy Zone - Newser
Larimar Therapeutics Raises $64.4 Million in Stock Offering - AInvest
Short interest data insights for Larimar Therapeutics Inc.Free Real-Time Market Sentiment Tracking Tool - Newser
Larimar Therapeutics Announces Closing of Underwritten - GlobeNewswire
Larimar Therapeutics Announces Closing of Underwritten Public Of - GuruFocus
Larimar Therapeutics Closes $69 Million Public Offering of Common Stock to Support Development of Pipeline Candidates - Quiver Quantitative
Larimar Therapeutics Raises $69M in Oversubscribed Public Offering - AInvest
Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares - GlobeNewswire
Rare Disease Biotech Larimar Secures $69M Windfall as Investors Rush to Oversubscribed Stock Offering - Stock Titan
Using R and stats models for Larimar Therapeutics Inc. forecastingShort-Term AI-Based Stock Price Forecast - Newser
What recovery options are there for Larimar Therapeutics Inc.Free High Win Rate Trading Opportunities - Newser
What indicators show strength in Larimar Therapeutics Inc.Predictive System for Long-Term Stock Forecast - Newser
Is it time to cut losses on Larimar Therapeutics Inc.Conservative Entry for High Return Setup Backed - metal.it
Is Larimar Therapeutics Inc. stock overhyped or has real potentialFree Trade Setups With AI Powered Filters - Newser
Will Larimar Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsReal Time Trade Opportunity Alerts Monitor Market Surges - metal.it
Larimar Therapeutics Announces Public Offering, Drops 20% in Share Price - AInvest
Larimar Therapeutics stock falls after $60 million public offering By Investing.com - Investing.com Canada
Larimar Therapeutics falls after $60 mln equity raise - TradingView
Multi asset correlation models including Larimar Therapeutics Inc.Free Breakout Momentum Picks With Protection - Newser
Larimar Therapeutics Inc Stock (LRMR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.02%
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):